Cargando…
Safety, tolerability and risk benefit analysis of tiotropium in COPD
COPD is a chronic disease and, like many other chronic diseases, there is no treatment to reverse the severity of the disease except for lung transplant. To date, no inhaled medications have been shown to improve survival. Tiotropium bromide is a long-acting inhaled anticholinergic drug for the trea...
Autores principales: | Oba, Yuji, Zaza, Tareq, Thameem, Danish M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650597/ https://www.ncbi.nlm.nih.gov/pubmed/19281075 |
Ejemplares similares
-
Role of tiotropium in the treatment of COPD
por: Rice, Kathryn L, et al.
Publicado: (2007) -
Tiotropium HandiHaler(®) in the treatment of COPD: A safety review
por: Kesten, Steven, et al.
Publicado: (2009) -
Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO(®) and OTEMTO(®) Studies
por: Buhl, Roland, et al.
Publicado: (2020) -
Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis
por: Halpin, David MG, et al.
Publicado: (2015) -
Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
por: Covelli, Henry, et al.
Publicado: (2015)